IMUX Nasdaq

Immunic, Inc.

IMUX | $1.25 1.63% 1.6% 200K

(0.0% 1d) (-4.6% 1m) (-20.5% 1y) (0.0% 2d) (0.8% 3d) (-2.4% 7d) (23.56% volume)
Earnings Calendar: 2023-05-11
Market Cap: $ 112,411,270
http://www.immunic-therapeutics.com
Sec Filling | Patents | 26 employees

(DE) Immunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA.

sclerosis autoimmunity multiple sclerosis immunology

add to watch list Paper trade email alert is off

Press-releases

Immunic to Host MS R&D Day and Participate in Investor Conferences in April 2024
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
IMUX | $1.25 1.63% 1.6% 200K

Health Technology

| 1.64% | O: 0.0% H: 3.28% C: 0.82%
day

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
IMUX | $1.25 1.63% 1.6% 200K

Health Technology

| -6.06% | O: 3.03% H: 2.94% C: 1.47%
patent

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
Published: 2024-02-29 (Crawled : 16:00) - biospace.com/
IMUX | $1.25 1.63% 1.6% 200K

Health Technology

| -11.43% | O: 0.71% H: 4.26% C: 3.9%
trials

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
Published: 2024-02-15 (Crawled : 13:00) - biospace.com/
IMUX | $1.25 1.63% 1.6% 200K

Health Technology

| -5.34% | O: 1.53% H: 5.26% C: 0.75%
year update financial results

Immunic to Participate in Investor and Scientific Conferences in February
Published: 2024-02-01 (Crawled : 23:00) - biospace.com/
IMUX | $1.25 1.63% 1.6% 200K

Health Technology

| 4.2% | O: 1.68% H: 2.49% C: 1.65%

Immunic Highlights 2023 Accomplishments and Upcoming Milestones
Published: 2024-01-05 (Crawled : 12:00) - prnewswire.com
IMUX | $1.25 1.63% 1.6% 200K

Health Technology

| -13.29% | O: 18.88% H: 1.76% C: -18.24%

Immunic, Inc. Announces Private Placement of up to $240 Million
Published: 2024-01-05 (Crawled : 12:00) - prnewswire.com
IMUX | $1.25 1.63% 1.6% 200K

Health Technology

| -13.29% | O: 18.88% H: 1.76% C: -18.24%
million

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
Published: 2023-11-02 (Crawled : 11:00) - biospace.com/
IMUX | $1.25 1.63% 1.6% 200K

Health Technology

| 19.23% | O: -1.92% H: 7.84% C: 4.9%
patent sclerosis treatment

Immunic to Participate in Scientific and Industry Conferences in November 2023
Published: 2023-10-26 (Crawled : 11:00) - biospace.com/
IMUX | $1.25 1.63% 1.6% 200K

Health Technology

| 13.76% | O: 0.0% H: 4.59% C: 0.92%

Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
Published: 2023-10-16 (Crawled : 11:00) - biospace.com/
IMUX | $1.25 1.63% 1.6% 200K

Health Technology

| 2.48% | O: 4.13% H: 0.0% C: -2.38%
caldose-1 week trial

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001193805-24-000325	4	2024-03-07	2024-03-04	Buy	A	64959	64959
0001193805-24-000325	4	2024-03-07	2024-03-04	Sell	D	19973	0
0001193805-24-000324	4	2024-03-07	2024-03-04	Buy	A	379959	379959
0001193805-24-000324	4	2024-03-07	2024-03-04	Sell	D	9986	0
0001193805-24-000323	4	2024-03-07	2024-03-04	Buy	A	64959	64959
0001193805-24-000323	4	2024-03-07	2024-03-04	Sell	D	19973	0
0001193805-24-000322	4	2024-03-07	2024-03-04	Buy	A	485000	485000
0001193805-24-000322	4	2024-03-07	2024-03-04	Sell	D	65000	0
0001193805-24-000321	4	2024-03-07	2024-03-04	Buy	A	259000	259000
0001193805-24-000321	4	2024-03-07	2024-03-04	Sell	D	100000	0